ClinicalTrials.gg
CompletedNCT04731623Updated Aug 9, 2022

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904

A Phase 1 interventional study of ION904 and Placebo in Healthy Volunteers, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 286 studies in Hypertension with a site in Canada — 27 open to participants now, 38 under way, 7 of them phase 3. Hypertension · Canada.

Enrollment
189th of 241
40 · median 169
Started
2021
with 16 others
Phase 1
12 of 286
3 open now
Registered
227th of 286
by date

Among the 286 studies in Hypertension with a site in Canada, this one is the 189th largest by enrollment of the 241 interventional ones that give a count, is one of 17 that started in 2021, is one of 12 in phase 1, and was the 227th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

27 of the 286 studies in Hypertension with a site in Canada are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Hypertension with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of ION904.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose escalation study of ION904 in up to 72 participants. Following a Screening Period of up to 28 days, eligible healthy participants will be randomized to treatment and receive a single, subcutaneous (SC) dose of the assigned study drug. Participants will be followed for up to 13 weeks after dosing.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Healthy Participants
  • Hypertension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be healthy males, or females of non-, aged 18 to 65 at the time of
  2. Females must be either surgically sterile or ; males must be abstinent, surgically sterile, or if engaged in sexual relations with a woman of childbearing potential, a highly effective method must be used from the time of signing the informed consent form until at least 13 weeks after the last dose of Study Drug or the healthy participant must be abstinent through this time period
  3. Willing to refrain from strenuous exercise/activity (for example heavy lifting, weight training, intense aerobics classes etc.) for at least 24 hours prior to study visits
  4. (BMI) requirements between 18 and 35 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in medical history or physical examination
  2. Uncontrolled arterial hypertension
  3. Active infection with (HIV), or or prior treatment for hepatitis C
  4. Treatment with another drug, biological agent, or device within 1 month of Screening
  5. History of bleeding diathesis or coagulopathy
  6. Regular use of alcohol within 6 months prior to screening, or use of soft drugs within 3 months prior to Screening, or hard drugs within 1 year prior to Screening, or positive urine drug screen at Screening
  7. History of any severe (e.g., anaphylaxis) drug allergies
  8. History of to other antisense oligonucleotides (ASOs)
  9. Concomitant medication restrictions: over-the-counter or prescription medications within 14 days, prior to dosing on Day 1. Accepted exceptions are:

    • Acetaminophen (paracetamol) up to 2 grams per day (g/d) or ibuprofen up to 2.4 g/day taken sporadically for analgesia
    • Thyroid hormone replacement therapy provided participant is stable on replacement therapy (and participant is euthyroid)
    • Other possible exceptions must be reviewed and acknowledged by the Investigator in consultation with Sponsor's Medical Monitor
  10. Blood donation of 50 to 499 mL within 30 days of Screening or of > 499 mL within 60 days of Screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ION904

    Single ascending dose of ION904 will be administered by SC injection on Day 1.

    Drug: ION904

  • Placebo comparator
    Placebo

    Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.

    Drug: Placebo

Interventions

  • DrugION904

    ION904 will be administered by SC injection.

  • DrugPlacebo

    Placebo (0.9% sterile saline) will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    Time frame: Up to Day 85

  2. Severity and dose relationship of TEAE

    Time frame: Up to Day 85

  3. Severity and dose relationship of clinically significant changes in laboratory values

    Time frame: Up to Day 85

  4. Severity and dose relationship of clinically significant changes in ECG

    Time frame: Up to Day 85

Secondary outcomes

  1. Changes in the Level of ION904 Target Biomarker

    Time frame: Up to Day 85

  2. Cmax: Maximum Observed Plasma Concentration of ION904

    Time frame: Up to Day 85

  3. Tmax: Time to Reach the Maximum Plasma Concentration of ION904

    Time frame: Up to Day 85

  4. t½λz: Plasma Elimination Half-life of ION904

    Time frame: Up to Day 85

  5. AUC0-t: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t for ION904

    Time frame: Up to Day 85

  6. Urine 0-24 Hour (hr) Excretion of ION904

    Time frame: Up to 24 hours

07

Study locations

1 site
  • BioPharma Services, Inc.
    Toronto, Ontario M9L 3A2, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Aug 2021, 5 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 5 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2021
First posted
Feb 1, 2021
StartActual
Feb 26, 2021
Primary completionActual
Aug 12, 2021
CompletionActual
Sep 11, 2021
Last update
Aug 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04731623
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Feb 26, 2021
Primary completion
Aug 12, 2021
Completion
Sep 11, 2021
Last update
Aug 9, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tonlamarsen

Start the discussion